Bristol-Myers Squibb will acquire Medarex, a biopharma focused on antibody-based therapeutics for the treatment life-threatening or debilitating diseases, for $2.4 ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.